

Table S6. Association of the concomitant use of CYP3A4/P-gp inhibitors or inducers with thromboembolic events among patients using edoxaban.

DDI	Cases (n=29), no. (%)	Controls (n=144), no. (%)	Univariate OR (95% CI)	<i>P</i> value	Model 1 ^a AOR (95% CI)	<i>P</i> value	Model 2 ^b AOR (95% CI)	<i>P</i> value	Model 3 ^c AOR (95% CI)	<i>P</i> value	Model 4 ^d AOR (95% CI)	<i>P</i> value
None DDI	18 (62.1)	77 (53.5)	1		1		1		1		1	
CYP3A4/P-gp inhibitors	7 (24.1)	50 (34.7)	0.52 (0.20-1.36)	0.182	0.41 (0.13-1.28)	0.124	0.46 (0.15-1.38)	0.166	0.35 (0.08-1.46)	0.149	0.43 (0.11-1.73)	0.236
CYP3A4/P-gp inducers	4 (13.8)	11 (7.6)	1.73 (0.49-6.15)	0.993	1.45 (0.35-6.03)	0.614	1.47 (0.38-5.65)	0.580	1.20 (0.20-7.11)	0.841	1.37 (0.27-7.02)	0.705
Both ^e	0 (0)	6 (4.1)	-	-	-	-	-	-	-	-	-	-

AOR: adjusted odds ratio; CI: confidence interval; CYP3A4: cytochrome P450 3A4; DDI: drug-drug interaction; OR: odds ratio

^a Adjusted for age, sex, income and comorbidities (hypertension, congestive heart failure, diabetes mellitus, chronic obstructive pulmonary disease [COPD], malignancy, dyslipidaemia, peripheral arterial occlusive disease [PAOD]).

^b Adjusted for age, sex, income and high risk of stroke.

^c Adjusted for age, sex, income, comorbidities (hypertension, congestive heart failure, diabetes mellitus, COPD, malignancy, dyslipidaemia, PAOD), medication use (warfarin, antiplatelet, calcium channel blockers, antihypertensives, hypoglycaemic agents, insulin, lipid-lowering agents, non-steroid anti-inflammatory drugs, proton pump inhibitors and corticosteroid).

^d Adjusted for age, sex, income, high risk of stroke, medication use (warfarin, antiplatelet, calcium channel blockers, antihypertensives, hypoglycemic agents, insulin, lipid-lowering agents, non-steroid anti-inflammatory drugs, proton pump inhibitors and corticosteroids).

^e Due to a small sample size, the OR could not be estimated accurately.